Agios sinks after Novo Nordisk reports sickle cell data

Shares of Agios Pharmaceuticals (AGIO) are sinking after Novo Nordisk (NVO) reported positive data in sickle cell disease. Novo’s etavopivat showed a 27% reduction in vaso-occlusive crisis events and a four month delay to first vaso-occlusive crisis events on top of standard of care in sickle cell disease patients. Shares of Agios, which is developing a sickle cell treatment, are down 15%, or $5.15, to $29.99 in premarket trading following the competitor data from Novo.